Peripheral T‐Cell Lymphomas in Southern Taiwan: Epidemiology, Treatment Patterns, and Long‐Term Outcomes Authors: Bo‐Yu Huang, Li‐Chang Chang, Sheng‐Yen Hsiao, Ya‐Ping Chen, Sin‐Syue Li, Pei‐An Fu, Chen Chang, Kung‐Chao Chang, Tsai‐Yun Chen, Ya‐Ting Hsu Published: 2026 ABSTRACT ABSTRACTPeripheral T‐cell lymphomas (PTCLs) are heterogeneous neoplasms with poor prognosis and marked geographic variation. Data from Taiwan remain limited. We conducted a 15‐year retrospective cohort study of 249 patients diagnosed with PTCL at two major centers in southern Taiwan between 2010 and 2024 to characterize regional epidemiology, real‐world treatment patterns, and survival outcomes. The cohort demonstrated subtype distribution typical of East Asia, with nodal T follicular helper cell lymphoma, angioimmunoblastic type (22%), extranodal NK/T‐cell lymphoma (21%), and PTCL‐NOS (15%) predominating. Most patients presented with high‐risk features: 71% Stage III–IV disease, 47% bone marrow involvement, and 64% elevated LDH. Median overall survival was 17.6 months, and event‐free survival was 6.4 months. Multivariable analysis identified ECOG performance status ≥ 2, elevated LDH, > 1 extranodal site, and age ≥ 60 years as four independent adverse prognostic factors. Frontline hematopoietic stem cell transplantation (HSCT) showed no significant improvement in outcomes; however, salvage chemotherapy followed by HSCT provided prolonged survival after relapse, with median survival after relapse not reached, compared with 6.1 months with salvage chemotherapy alone. These findings underscore PTCL's persistently poor outcomes and the essential role of salvage HSCT in durable survival. Addressing biological complexity and improving therapeutic strategies remain critical for advancing care.Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission Introduction Peripheral T‐cell lymphomas (PTCLs) comprise heterogeneous neoplasms with poor prognosis. Subtype distribution varies geographically, with entities such as extranodal NK/T‐cell lymphoma (ENKTL) and adult T‐cell leukemia/lymphoma (ATLL) being more prevalent in East Asia and Latin America than Western countries [1, 2, 3]. This variability underscores the importance of region‐specific data for understanding local disease patterns and tailoring therapeutic strategies. Despite diagnostic advances and class‐specific therapy approvals, most PTCL subtypes demonstrate dismal outcomes, with a median survival after relapse of 5.8 months and a 3‐year survival rate after relapse of 23% [4]. While upfront autologous hematopoietic stem‐cell transplantation (auto‐HSCT) is often recommended for consolidation, its benefit remains debated. Access to targeted therapies is limited in many healthcare systems, including Taiwan's [5, 6]. Consequently, real‐world outcomes may differ substantially from pivotal clinical trials enrolling younger, fitter patients. Large‐scale, long‐term PTCL data on clinical characteristics, treatment patterns, and survival outcomes from Taiwan are scarce. We conducted a 15‐year retrospective analysis at two major centers in southern Taiwan to characterize regional epidemiology, identify independent prognostic factors, and assess real‐world outcomes. Materials and Methods Study Design and Setting This retrospective, observational cohort study was conducted at two major institutions in southern Taiwan: National Cheng Kung University Hospital (NCKUH), a tertiary academic medical center, and Chi‐Mei Hospital (CMH), Liouying Branch, a regional teaching hospital. Consecutive patients diagnosed between January 1, 2010, and December 31, 2024, were reviewed. Study Population Eligible participants were adults (≥ 18 years) with confirmed diagnosis of PTCL retrospectively identified through electronic medical record databases. We excluded patients with limited‐stage primary cutaneous T‐cell lymphoma, requiring only observation or local management, differing from systemic treatment paradigm. Patients were also excluded if they had incomplete baseline clinicopathologic data, loss to follow‐up, or transfer to another institution (primarily for geographic convenience) prior to treatment initiation. All diagnoses were established by board‐certified hematopathologists using morphology‐guided immunohistochemistry and, when required, in situ hybridization or molecular assays, harmonized to the 5th edition of the WHO Classification of Haematolymphoid Tumours [7]. Consequently, the NCKUH registry initially identified 184 cases. We excluded 10 patients who were lost to follow‐up, five who were transferred before treatment initiation, and one with incomplete baseline data, leaving 168 evaluable patients. The CMH registry contained 65 cases; 44 were excluded due to insufficient documentation of baseline characteristics, staging parameters, treatment details, or transplantation status, leaving 21 evaluable patients. The final analytic cohort comprised 189 patients for outcome analysis (Figure S1). Data Collection and Variables Clinical data, including baseline demographics, laboratory parameters, disease characteristics, treatment details, response assessments, and survival outcomes, were extracted from the electronic medical records using a standardized, prespecified case report form. Data quality was ensured through cross‐validation, with discrepancies resolved by consensus review. The study database was finalized and locked on December 31, 2024. Study Outcomes The primary objective was to characterize the epidemiology and clinical outcomes of PTCL in southern Taiwan. Overall survival (OS) was defined as the time from definitive histopathologic diagnosis to death from any cause, with surviving patients censored on December 31, 2024. Event‐free survival (EFS) was measured from diagnosis to death from any cause, radiologically confirmed progression by computed tomography or positron emission tomography, salvage therapy initiation, or first‐line treatment modification. Event‐free patients were censored at the data lock date. Secondary objectives included characterization of real‐world treatment patterns, emphasizing the utilization and clinical impact of HSCT in both frontline consolidation and salvage settings, and identifying independent prognostic factors for OS and EFS. Statistical Analysis Continuous variables were summarized as mean ± standard deviation or median (interquartile range [IQR]), and categorical variables as counts and percentages. Group differences were analyzed using Student's t‐test for continuous variables and the chi‐square test for categorical variables. OS and EFS were estimated using the Kaplan–Meier method with the log‐rank comparison. To identify independent prognostic factors for OS, variables including age, ECOG status, number of extranodal sites, Ann Arbor stage, LDH, bone marrow involvement, etoposide‐containing regimen, and frontline HSCT were evaluated using Cox proportional hazards regression. Variables demonstrating statistical significance in univariable analysis were included in the multivariable model to calculate hazard ratios (HRs) with 95% confidence intervals (CI). Statistical significance was defined as a two‐sided p < 0.05. Analyses were performed using RStudio 2025.05.0 + 496, utilizing the survival, survminer, and ggplot2 packages. Results Patient Characteristics A total of 249 patients diagnosed with PTCL through December 2024 were initially identified from the registries of NCKUH (n = 184) and CMH (n = 65). The median age at diagnosis was 62 years (range, 20–95), and 62% of patients were male. Median follow‐up was 13 months (IQR, 4–54). The PTCL subtype distribution was as follows: 57 cases of nodal T follicular helper cell lymphoma, angioimmunoblastic type (nTFHL‐AI, 22%), 50 cases of ENKTL (21%), 38 cases of PTCL, not otherwise specified (PTCL‐NOS, 15%), 15 cases of T‐cell large granular lymphocytic leukemia (T‐LGL, 6%), 12 cases of ATLL (5%), 11 cases of ALK‐negative ALCL (ALK− ALCL, 4%), 9 cases of subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL, 3%), 7 cases of ALK‐positive anaplastic large‐cell lymphoma (ALK+ ALCL, 3%), and 4 cases of enteropathy‐associated T‐cell lymphoma (EATL, 2%). These nine subtypes collectively accounted for 81% of the entire cohort, with the remaining 19% comprising rarer entities (Figure S2). Epidemiological data from Taiwan demonstrate that the crude incidence rate of PTCL remained stable at approximately 1.4–1.6 cases per 100,000 people annually between 2010 and 2022 [8]. However, the proportion of T‐cell lymphoma among all non‐Hodgkin lymphomas (NHL) decreased from 15.9% to 10.2% during the same period (Figure S3), indicating a more significant rise in B‐cell NHL incidence. Subtype‐specific trends from the Taiwan Cancer Registry revealed an increasing incidence of ENKTL and nTFHL‐AI, with a decreasing incidence of PTCL‐NOS (Figure S4A). However, the three most common subtypes (nTFHL‐AI, ENKTL, and PTCL‐NOS) in our registry cohort remained relatively stable over the 15‐year study period (Figure S4), with ENKTL showing an initial decline and then recovery, nTFHL‐AI gradually increasing, and PTCL‐NOS fluctuating (Figure S4B). After applying exclusion criteria, 189 patients were eligible for outcome analysis. The majority (69%) had an ECOG performance status of 0–1. A substantial proportion of patients presented with adverse prognostic features: 71% had Ann Arbor Stage III–IV disease, 47% had bone marrow involvement, and 64% demonstrated elevated LDH levels. High‐risk disease was prevalent, with 29% having an IPI score of 4–5 and 60% classified as high‐intermediate to high‐risk by PIT score. Regarding the response to frontline treatment, the overall response rate (ORR) was 52%, comprising 26% complete and 26% partial remission. Furthermore, 3% of patients had stable disease, and 21% experienced disease progression. Notably, treatment efficacy was not assessable in 24% of patients; the principal reasons included poor performance status precluding systemic therapy, treatment refusal, or early death prior to the first restaging assessment (Table 1). TABLE 1Baseline characteristics of patients included for outcome analysis.Patient number, n 189Histological subtype, n (%)ATLL9 (5)ALK− ALCL6 (3)ALK+ ALCL6 (3)EATL4 (2)ENKTL40 (21)nTFHL‐AI44 (23)PTCL‐NOS30 (16)SPTCL9 (5)T‐LGL7 (4)Other34 (18)ECOG performance status, n (%)0–1130 (69)2–459 (31)Ann Arbor stage at diagnosis, n (%)I–II45 (24)III–IV134 (71)Missing10 (5)IPI score at diagnosis, n (%)Low risk (0–1)37 (20)Low‐intermediate risk (2)40 (21)High‐intermediate risk (3)41 (22)High risk (4–5)54 (29)Missing17 (8)PIT score at diagnosis, n (%)Low risk (0)21 (11)Low‐intermediate risk (1)30 (16)High‐intermediate risk (2)43 (23)High risk (3–4)70 (37)Missing25 (13)Bone marrow involvement at diagnosis, n (%)Involved88 (47)Not involved84 (44)Missing17 (9)Elevated LDH (> ULN)120 (64)Response to frontline treatment, n (%)Complete remission50 (26)Partial remission50 (26)Stable disease5 (3)Progressive disease39 (21)Missing or not assessed45 (24) Note: The cohort for outcome analysis (n = 189) excluded patients with incomplete baseline clinicopathologic data, loss to follow‐up or transfer to another institution prior to treatment initiation. The IPI score is based on five variables (age, stage, LDH, ECOG performance status, and number of extranodal sites), and the PIT score includes four variables (age, ECOG performance status, LDH level, and bone marrow involvement). The “Other” category includes: aggressive NK cell leukemia, EBV+ nodal T and NK cell lymphoma, monomorphic epitheliotropic intestinal T‐cell lymphoma, nodal TFH cell lymphoma, follicular type, nodal TFH cell lymphoma, NOS, post‐transplant lymphoproliferative disorder, systemic EBV‐positive T‐cell lymphoma of childhood, T‐prolymphocytic leukemia, hepatosplenic T‐cell, metastatic anaplastic large cell lymphoma, T‐cell lymphoblastic lymphoma, EBV+ TCL with hemophagocytosis, primary cutaneous anaplastic large cell lymphoma, primary cutaneous CD4‐positive small or medium T‐cell lymphoproliferative disorder, and primary cutaneous gamma/delta T‐cell lymphoma.John Wiley & Sons, Ltd. Baseline characteristics of patients included for outcome analysis. Note: The cohort for outcome analysis (n = 189) excluded patients with incomplete baseline clinicopathologic data, loss to follow‐up or transfer to another institution prior to treatment initiation. The IPI score is based on five variables (age, stage, LDH, ECOG performance status, and number of extranodal sites), and the PIT score includes four variables (age, ECOG performance status, LDH level, and bone marrow involvement). The “Other” category includes: aggressive NK cell leukemia, EBV+ nodal T and NK cell lymphoma, monomorphic epitheliotropic intestinal T‐cell lymphoma, nodal TFH cell lymphoma, follicular type, nodal TFH cell lymphoma, NOS, post‐transplant lymphoproliferative disorder, systemic EBV‐positive T‐cell lymphoma of childhood, T‐prolymphocytic leukemia, hepatosplenic T‐cell, metastatic anaplastic large cell lymphoma, T‐cell lymphoblastic lymphoma, EBV+ TCL with hemophagocytosis, primary cutaneous anaplastic large cell lymphoma, primary cutaneous CD4‐positive small or medium T‐cell lymphoproliferative disorder, and primary cutaneous gamma/delta T‐cell lymphoma. Survival Outcomes The median OS was 17.6 months (95% CI 12.0–25.6 months), while the median EFS was 6.4 months (95% CI 5.5–9.2 months) (Figure 1). When divided by the three most common subtypes, median OS was 23.1 months for ENKTL, compared with 18.7 months for nTFHL‐AI and 10.3 months for PTCL‐NOS. These differences were not statistically significant (p = 0.973; Figure S5), likely because of small subgroup sizes and substantial heterogeneity within each category. Survival outcomes of PTCL patients. (A) OS of the entire cohort showed a median survival of 17.6 months (95% CI 12.0–25.6 months). (B) EFS for the entire cohort was 6.4 months (95% CI 5.5–9.2 months). (C) OS stratified by diagnostic period demonstrated median survival of 65.4 months (95% CI 16.0 months–not reached) for 2010–2014, 13.7 months (95% CI 6.8–33.9 months) for 2015–2019, and 13.9 months (95% CI 8.8 months‐not reached) for 2020–2024. To evaluate temporal trends, patients were further stratified into three 5‐year diagnostic cohorts: the median OS was 65.4 months for the 2010–2014 cohort, 13.7 months for the 2015–2019 cohort, and 13.9 months for the 2020–2024 cohort (p = 0.144) (Figure 1C). The 2010–2014 cohort presented with notably more favorable baseline characteristics, including younger age, better performance status, lower disease burden reflected by reduced rates of LDH elevation, and less advanced disease (Table S1). Regarding frontline treatment, CHOP‐based regimens predominated. Approximately one‐tenth (11.6%, n = 22) received etoposide‐containing regimens, commonly CHOEP (CHOP + etoposide). Despite etoposide intensification, outcomes showed no statistical significance, with median OS of 17.5 versus 16.1 months (HR 0.89; 95% CI 0.48–1.64; p = 0.659), and a median EFS of 10.0 versus 6.1 months (p = 0.974) compared with CHOP‐based regimens alone (Figure 2). Survival outcomes stratified by etoposide intensification as first‐line systemic treatment. (A) OS in patients treated with etoposide‐containing regimens showed a median survival of 17.5 months (95% CI 9.7 months–not reached) compared to 16.1 months (95% CI 6.8–65.4 months) in patients without etoposide‐containing regimens (p = 0.659). (B) EFS in patients treated with etoposide‐containing regimens was 10.0 months (95% CI 3.8–22.5 months), compared with 6.1 months (95% CI 5.0–9.2 months) in patients without etoposide‐containing regimens (p = 0.974). Notably, significant baseline imbalances highlight potential confounding by indication (Table S2). Patients receiving etoposide‐containing regimens had similar age and sex distribution, but demonstrated higher‐risk disease features, including advanced‐stage disease, elevated LDH, bone marrow involvement (81.8% vs. 52.5%, p = 0.015), and better ECOG performance status. These baseline differences reveal that clinicians preferred etoposide intensification for patients with good performance who had more aggressive and systemically disseminated disease. The lack of survival benefit reflects the inherently worse prognosis of patients with advanced disease and highlights the limited efficacy of cytotoxic intensification in PTCL, aligning with the absence of randomized evidence supporting routine etoposide intensification in most PTCL subtypes. Impact of Transplantation on Survival Within the cohort, 26 patients (14%) underwent HSCT: 14 received frontline HSCT as consolidation therapy, and 14 underwent salvage chemotherapy followed by HSCT for relapsed/refractory disease. Two patients who initially received frontline HSCT subsequently required salvage HSCT upon disease relapse (Table S3). Patients who received frontline HSCT as consolidation did not demonstrate statistical significance in outcomes, with median OS not reached versus 16.4 months (p = 0.082) and median EFS of 15.2 versus 6.1 months (p = 0.205) (Figure 3). To specifically address the outcomes of frontline treatment failure, we analyzed the survival after relapse for the relapsed/refractory population. The overall median survival after relapse for the entire relapsed/refractory cohort was 6.5 months. Nevertheless, transplantation provided a substantial survival benefit: the median survival after relapse was not reached for patients successfully bridged to transplantation, compared with only 6.1 months for those managed with salvage chemotherapy alone (p < 0.001; Figure 4). Survival outcomes according to frontline transplantation. (A) OS in patients who received frontline HSCT showed a median survival not reached (95% CI 16.1 months–not reached) compared to 16.4 months (95% CI 9.7–25.1 months) in patients without frontline HSCT (p = 0.082). (B) EFS in patients who received frontline HSCT was 15.2 months (95% CI 10.0 months–not reached), compared with 6.1 months (95% CI 4.9–8.0 months) in patients without frontline HSCT (p = 0.205). Survival after relapse in the relapsed and refractory cohort. (A) The median survival after relapse was 6.5 months (95% CI 5.0–14.6 months). (B) The median survival after relapse for patients undergoing salvage chemotherapy followed by HSCT was not reached, compared to 6.1 months (95% CI 4.1–9.9 months) for those managed with salvage chemotherapy alone (p < 0.001). Univariate and Multivariate Analysis In univariate analysis, six of eight variables were significantly associated with OS. Adverse prognostic factors included age ≥ 60 years (HR 1.79; 95% CI 1.22–2.62; p = 0.003), ECOG performance status ≥ 2 (HR 3.19; 95% CI 2.20–4.62; p < 0.001), > 1 extranodal site (HR 2.04; 95% CI 1.40–2.97; p < 0.001), Ann Arbor Stage III–IV (HR 1.81; 95% CI 1.12–2.91; p = 0.015), elevated LDH (HR 2.44; 95% CI 1.55–3.85; p < 0.001), and bone marrow involvement (HR 1.63; 95% CI 1.11–2.39; p = 0.013). Neither etoposide‐containing regimens (HR 0.86; 95% CI 0.48–1.53; p = 0.605) nor frontline HSCT (HR 0.48; 95% CI 0.21–1.10; p = 0.084) reached statistical significance. In multivariable analysis incorporating six univariable factors, four emerged as independent predictors of inferior OS: age ≥ 60 years (HR 1.59; 95% CI 1.06–2.37), ECOG performance status ≥ 2 (HR 2.19; 95% CI 1.45–3.31), > 1 extranodal site (HR 1.70; 95% CI 1.14–2.52), and elevated LDH (HR 2.00; 95% CI 1.14–3.53). Notably, advanced Ann Arbor stage and bone marrow involvement lost statistical significance in the multivariable model (Table 2). TABLE 2Cox proportional hazards regression analysis identifying prognostic factors for overall survival from risk‐defining events in patients with PTCLs.VariableSubgroupNo.Univariate HR (95% CI) p valueMultivariable HR (95% CI) p valueAge< 6078ReferenceReference≥ 601111.79 (1.22–2.62)0.0031.59 (1.06–2.37)0.024ECOG0–1130ReferenceReference2–4593.19 (2.20–4.62)< 0.0012.19 (1.45–3.31)< 0.001Extranodal site≤ 1118ReferenceReference> 1652.04 (1.40–2.97)< 0.0011.70 (1.14–2.52)0.009Ann Arbor stageI–II45ReferenceReferenceIII–IV1341.81 (1.12–2.91)0.0150.78 (0.42–1.47)0.445LDHNormal59ReferenceReference> ULN1202.44 (1.55–3.85)< 0.0012.00 (1.14–3.53)0.016BM involvementNot involved84ReferenceReferenceInvolved881.63 (1.11–2.39)0.0131.21 (0.78–1.87)0.398EtoposideNot containing167ReferenceContaining220.86 (0.48–1.53)0.605HSCTNon‐frontline175ReferenceFrontline140.48 (0.21–1.10)0.084 Note: In univariable analysis, poor ECOG performance status (2–4), elevated LDH, the presence of > 1 extranodal site, age ≥ 60 years, advanced Ann Arbor stage (III–IV), high‐risk IPI score (2–4), and bone marrow involvement were identified as significant predictors of shorter overall survival. Conversely, treatment with etoposide‐containing regimens or frontline HSCT did not significantly impact survival. Upon multivariable analysis, poor ECOG status, elevated LDH, age ≥ 60 years, and > 1 extranodal site remained independent prognostic factors for OS.John Wiley & Sons, Ltd. Cox proportional hazards regression analysis identifying prognostic factors for overall survival from risk‐defining events in patients with PTCLs. Note: In univariable analysis, poor ECOG performance status (2–4), elevated LDH, the presence of > 1 extranodal site, age ≥ 60 years, advanced Ann Arbor stage (III–IV), high‐risk IPI score (2–4), and bone marrow involvement were identified as significant predictors of shorter overall survival. Conversely, treatment with etoposide‐containing regimens or frontline HSCT did not significantly impact survival. Upon multivariable analysis, poor ECOG status, elevated LDH, age ≥ 60 years, and > 1 extranodal site remained independent prognostic factors for OS. ENKTL Subgroup Analysis Among the 40 ENKTL patients (median age 59.5 years; 68% male), 70% presented with early‐stage (I/II) disease. LDH was elevated in 55% of cases, and bone marrow involvement was present in 12%. EBV viral load was measured in 23 patients (58%), of whom 57% had detectable viremia. Concurrent chemoradiotherapy (CCRT) with DeVIC‐based regimens was the most common first‐line therapy (55%), followed by SMILE (28%); only two patients (5%) received CHOP/CHOEP. Overall, 48% received L‐asparaginase‐containing therapy at any line (73% of advanced‐stage vs. 39% of early‐stage patients), and 75% received RT. Checkpoint inhibitor exposure was limited to three patients (8%) in the relapsed/refractory setting. Seven patients (18%) underwent HSCT, predominantly as salvage (n = 6). Among 33 evaluable patients, the ORR was 70% (complete remission, CR 48%), with higher response rates in early‐stage (ORR 77%) than advanced‐stage disease (ORR 43%). After a median follow‐up of 11 months, 24 patients (60%) had died. Use of Targeted Agents Four ALCL patients (one ALK+, three ALK−) received frontline regimens containing brentuximab vedotin (BV). Two achieved CR but relapsed; two had primary refractory disease. The ALK+ patient was salvaged with ESHAP followed by autologous and allogeneic HSCT and remained alive at 44 months. Among ALK− patients, survival ranged from 2 to 40 months. Eleven patients received pralatrexate for relapsed/refractory disease (nTFHL‐AI, n = 6; PTCL‐NOS, n = 4). One nTFHL‐AI patient achieved durable CR lasting more than 6 years; one PTCL‐NOS patient refractory to pralatrexate was successfully bridged to autologous HSCT with BV and remained alive at 68 months. The remaining patients were refractory or relapsed without consolidative transplantation. Discussion This 15‐year retrospective study characterizes the regional epidemiology and real‐world outcomes of PTCL at two institutions in southern Taiwan. The subtype distribution, notable for high prevalence of ENKTL and nTFHL‐AI, aligns with established epidemiological patterns in East Asia. Most patients presented with high‐risk features and advanced‐stage disease, resulting in a dismal median OS of only 17.6 months. Critically, no survival improvement was observed over the study period; median OS remained similar between cohorts diagnosed in different eras. While the benefit of upfront transplantation consolidation was not statistically significant, salvage chemotherapy followed by HSCT conferred a durable survival advantage for patients with relapsed/refractory disease. Our multivariable analysis identifies four independent prognostic variables (ECOG performance status ≥ 2, elevated LDH, > 1 extranodal site, and age ≥ 60 years) that closely replicate the standard IPI but notably exclude Ann Arbor stage. This reduced utility of anatomical staging aligns with the PTCL‐specific prognostic index, emphasizing that intrinsic patient fitness and biological tumor burden indicators are more effective than traditional staging for predicting PTCL clinical outcomes. We present data from two analytical perspectives. First, the epidemiological analysis includes all 249 consecutively diagnosed patients to provide a comprehensive picture of PTCL subtype distribution and temporal trends. Second, the outcome analysis focuses on 189 patients who met eligibility criteria, including adequate baseline clinical data and follow‐up for survival modeling. Patients with missing critical prognostic variables or immediate transfer to other facilities were excluded from outcome analyses but retained in epidemiological reporting. This approach ensures comprehensive epidemiological coverage while maintaining statistical rigor for prognostic analyses. The geographic heterogeneity in PTCL distribution may reflect differences in environmental exposures, viral infections (such as EBV and HTLV‐1), genetic factors, or diagnostic practices [9, 10, 11]. Advances in nosology have separated entities previously grouped under PTCL‐NOS, especially T follicular helper‐phenotype and EBV‐positive tumors, reshaping epidemiologic comparisons [7, 12, 13]. In current global data, PTCL‐NOS, nTFHL‐AI, and ALK− ALCL make up 35%, 18%, and 17% of cases, respectively, based on the International T‐Cell Project from 2006 to 2018 [14]. Asian populations show distinct patterns: nTFHL‐AI is mostly found in Japan, and primary nodal EBV‐positive T/NK‐cell lymphomas are almost exclusively reported from Asian centers [1, 15]. Compared with these global patterns, Taiwan's epidemiology exhibits a distinct distribution, with PTCL‐NOS as the most common subtype, followed by ENKTL and nTFHL‐AI. The stagnant survival rates over the past 15 years underscore critical barriers to treatment access. While targeted agents such as HDAC inhibitors, BV, and pralatrexate have improved outcomes in western countries [16, 17], options in Taiwan remain severely limited. This disparity is primarily driven by delayed regulatory approvals, limited reimbursement coverage, and high out‐of‐pocket costs, especially in southern Taiwan, where lower regional incomes further restrict access. Only 7.9% of patients in our cohort received PTCL‐specific treatments beyond CHOP‐based regimens, with just four receiving BV as initial therapy and 11 receiving pralatrexate for salvage. Moreover, accurate subtype classification often requires specialized hematopathology expertise, which is not always available, potentially causing delays in diagnosis and proper management. Frontline HSCT showed a trend toward better OS and EFS, but differences weren't statistically significant. Selection bias in observational studies likely influenced results, favoring patients with better features, but trends match prospective studies showing survival benefits with upfront autologous HSCT in PTCL [5, 6, 18, 19]. This concordance suggests a genuine therapeutic benefit beyond selection effects alone. Despite newer agents, outcomes for relapsed/refractory PTCL remain poor [20, 21]. Our study demonstrates that salvage chemotherapy followed by HSCT confers a substantial survival benefit. This finding aligns with prior studies documenting the efficacy of salvage transplantation in relapsed/refractory PTCL [4, 22]. However, this finding may be influenced by selection bias. Compared with patients receiving salvage chemotherapy alone, the HSCT cohort was younger, had better ECOG performance status, and had less bone marrow involvement (Table S4), suggesting that the apparent survival advantage may partly reflect baseline fitness and the ability to bridge to intensive therapy. The survival curve for transplanted patients plateaued at approximately 2 years, suggesting durable disease control. Our ENKTL subset showed clinical characteristics and treatment patterns consistent with the contemporary literature. The near‐complete abandonment of CHOP‐based therapy (5%) and predominant use of DeVIC/CCRT‐ and SMILE‐based regimens reflect the established role of non‐anthracycline approaches in this entity. The ORR of 70% and CR rate of 48% are comparable to real‐world series [23, 24, 25]. A recent nationwide Korean study reported 5‐year PFS and OS rates of 47.5% and 49.9%, respectively, among treated ENKTL patients, with transplantation conferring an OS benefit. In that cohort, SMILE was the most commonly used regimen for extranodal lymphomas, consistent with the treatment pattern observed in our series [26]. The low rate of frontline HSCT consolidation in our cohort, particularly for advanced‐stage patients, may represent an area for improvement given emerging data demonstrating favorable outcomes with transplantation in this population [24, 26]. In contrast to the nodal PTCL subtypes in our cohort, the ENKTL subset was characterized by early‐stage presentation, a non‐anthracycline‐based treatment approach, and higher utilization of radiation therapy, reflecting the distinct biology and treatment paradigm of this entity. This retrospective study is limited by selection bias, missing data, insufficient statistical power for subgroups, lack of molecular profiling, and potential overestimation of treatment efficacy due to the exclusion of non‐assessable patients. The 15‐year timeframe encompasses evolving diagnostic criteria and treatments, making temporal analyses more complex. Geographic restrictions may limit generalizability. Recent enrollees have inadequate follow‐up for long‐term evaluation. Representing Taiwan's largest PTCL cohort, we demonstrate persistently stagnant survival, especially among elderly, frail patients with high tumor burden. Salvage chemotherapy followed by HSCT was the only intervention providing durable survival. These findings highlight critical unmet needs, requiring prospective, biomarker‐driven studies to refine risk stratification and transplant candidate selection, as well as health policies to ensure equitable access to novel agents in resource‐limited settings. Author Contributions Bo‐Yu Huang: conceptualization, methodology, data curation, validation, writing – review and editing, visualization. Li‐Chang Chang: conceptualization, methodology, supervision, resources, data curation, validation, writing – review and editing. Sheng‐Yen Hsiao: resources. Ya‐Ping Chen: resources. Sin‐Syue Li: resources. Pei‐An Fu: resources. Chen Chang: resources, validation. Kung‐Chao Chang: resources, validation. Tsai‐Yun Chen: conceptualization, supervision, validation. Ya‐Ting Hsu: conceptualization, methodology, supervision, resources, validation, visualization Funding The authors have nothing to report. Ethics Statement This study was exempt from institutional review board approval per institutional guidelines for retrospective studies with de‐identified data. Consent This study was submitted without patient‐specific information. All personal identifying information has been removed. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supporting file 1: jha270302‐sup‐0001‐figureS1.png Supporting file 2: jha270302‐sup‐0002‐figureS2.png Supporting file 3: jha270302‐sup‐0003‐figureS3.png Supporting file 4: jha270302‐sup‐0004‐figureS4.tif Supporting file 5: jha270302‐sup‐0005‐figureS5.png Supporting file 6: jha270302‐sup‐0006‐SuppMat.pdf